Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

计划入组 519 人 · 首次发布于 2023 年 12 月 15 日

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

计划入组 120 人 · 首次发布于 2024 年 3 月 8 日

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

计划入组 128 人 · 首次发布于 2024 年 3 月 22 日

Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian)

Interleukin-1 alpha (Dainippon)

anti-interleukin-7 receptor alpha monoclonal antibody

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Alpha Metallurgical

United States

China Medical System's MG-K10 Advances to Phase III Trials for Chronic Spontaneous Urticaria Treatment

Keymed Biosciences' Stapokibart Receives NMPA Approval for Seasonal Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyposis

Severe Asthma Pipeline Shows Promise with Over 50 Therapies in Development